
Veru VERU
€ 2.05
0.84%
Quartalsbericht 2025-Q4
hinzugefügt 11.02.2026
Veru EV 2011-2026 | VERU
EV Jährlich Veru
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111 M | 121 M | 535 M | 407 M | 190 M | 147 M | 82 M | 45.8 M | 29.5 M | 49 M | 128 M | 266 M | 189 M | 117 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 535 M | 29.5 M | 173 M |
EV anderer Aktien in der Arzneimittelhersteller
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Assertio Holdings
ASRT
|
238 M | $ 18.05 | 0.17 % | $ 116 M | ||
|
Agile Therapeutics
AGRX
|
25.3 M | - | 10.11 % | $ 58.2 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
6.79 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
28.5 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
737 M | - | - | $ 754 M | ||
|
Catalent
CTLT
|
16.7 B | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
3.37 M | - | - | $ 50.1 M | ||
|
Alimera Sciences
ALIM
|
197 M | - | - | $ 142 M | ||
|
Athenex
ATNX
|
209 M | - | -23.39 % | $ 1.76 M | ||
|
Eagle Pharmaceuticals
EGRX
|
457 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
-710 M | - | - | $ 28.9 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
756 M | - | - | $ 2.06 B | ||
|
Evoke Pharma
EVOK
|
7.15 M | - | - | $ 36.6 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
124 M | $ 3.15 | 1.94 % | $ 44.3 M | ||
|
Cronos Group
CRON
|
3.84 B | $ 2.53 | -1.88 % | $ 1.35 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
10.2 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
284 M | - | 2.45 % | $ 38.1 M | ||
|
Bausch Health Companies
BHC
|
29.9 B | $ 5.58 | -0.53 % | $ 2.04 B | ||
|
Harrow Health
HROW
|
2.21 B | $ 36.02 | 0.25 % | $ 1.32 B | ||
|
Aurora Cannabis
ACB
|
106 M | $ 3.33 | -2.99 % | $ 86.3 M | ||
|
Canopy Growth Corporation
CGC
|
459 M | $ 1.03 | -1.92 % | $ 111 M | ||
|
OrganiGram Holdings
OGI
|
456 M | $ 1.38 | -1.44 % | $ 402 M | ||
|
Neoleukin Therapeutics
NLTX
|
-80.1 M | - | - | $ 193 M | ||
|
Jupiter Wellness
JUPW
|
3.7 M | - | - | $ 33.6 M | ||
|
Relmada Therapeutics
RLMD
|
251 M | $ 7.32 | 0.34 % | $ 289 M | ||
|
Lannett Company
LCI
|
648 M | - | 1.15 % | $ 7.11 M | ||
|
Evolus
EOLS
|
467 M | $ 4.31 | 0.94 % | $ 278 M | ||
|
Emergent BioSolutions
EBS
|
1.2 B | $ 7.9 | -0.75 % | $ 404 M | ||
|
Sundial Growers
SNDL
|
-17.5 M | $ 1.37 | -3.52 % | $ 3.37 M | ||
|
Tilray
TLRY
|
1.96 B | $ 6.4 | -2.59 % | $ 3.96 B | ||
|
Organogenesis Holdings
ORGO
|
392 M | $ 2.35 | -1.26 % | $ 309 M | ||
|
Pacira BioSciences
PCRX
|
1.68 B | $ 23.71 | -0.34 % | $ 1.1 B | ||
|
PetIQ
PETQ
|
280 M | - | 1.64 % | $ 400 M | ||
|
Viatris
VTRS
|
41.3 B | $ 13.43 | -0.33 % | $ 16.1 B | ||
|
ProPhase Labs
PRPH
|
145 M | - | - | $ 5.07 M | ||
|
cbdMD
YCBD
|
7.85 M | $ 0.66 | -2.96 % | $ 2.85 M | ||
|
Radius Health
RDUS
|
700 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
220 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
312 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
26.3 M | $ 1.0 | - | $ 49.9 M | ||
|
PLx Pharma
PLXP
|
73.8 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
616 M | $ 7.87 | -1.87 % | $ 689 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
7.57 M | $ 2.26 | -0.88 % | $ 2.8 M | ||
|
Zomedica Corp.
ZOM
|
2.62 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-22.6 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
43.3 M | $ 0.91 | -0.02 % | $ 32.7 M | ||
|
Tricida
TCDA
|
506 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
10.7 M | $ 0.63 | - | $ 2.7 M | ||
|
TherapeuticsMD
TXMD
|
26.3 M | $ 2.13 | 3.14 % | $ 24.6 M |